Cellectis - Adr (CLLS) 13F Investor Activity Report (Q2 2026)

CLLS ranks #7725 out of 37503 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

27 institutions disclose a position in CLLS, but none treat it as a major bet — even B Group, Inc., its most concentrated holder, allocates just 4.6% of its own portfolio to it.

UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC has trimmed its CLLS position for two straight quarters, cutting it by $7.4M while still holding $7.9M.

CLLS is down 1.5% today, and institutions have been net sellers of $2.0M this quarter — today's price move and the underlying institutional flow are pointing the same direction.

CLLS reported a net loss of $107.4M over the trailing twelve months.

• Not yet profitable — net loss of $107.4M over the trailing twelve months
• Revenue grew 26.8% year over year
• Net income declined year over year, from -$103.2M to -$107.4M
• Operating cash flow was negative, using $39.4M in cash
• Current ratio of 1.62x — enough short-term assets to cover short-term liabilities
• Liabilities run 3.28x equity — a highly leveraged balance sheet worth noting